Transactions
18
Insider / REGENERON PHARMACEUTICALS, INC.
Zoghbi Huda Y
Director at REGENERON PHARMACEUTICALS, INC.
- Ticker
- REGN
- First filing on record
- January 6, 2026
- Latest trade on record
- August 10, 2026
- SEC filings
- EDGAR ↗
Zoghbi Huda Y, Director at REGENERON PHARMACEUTICALS, INC., has disclosed 18 transactions in REGN since January 6, 2026: 0 purchases (0 open-market buys) and 12 sales, worth about $2.8M at the reported prices. The latest was filed August 12, 2026, 2 days after the trade.
Open-market buys
0
Sales
12
Avg. disclosure lag
3.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Zoghbi Huda Y made no purchases and 12 sales worth $1.9M, plus 6 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Zoghbi Huda Y has traded 1 stock on record; the largest by dollars is REGN.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 3 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| S | Open-market sale | 12 | 2,438 | $1.9M |
| M | Option exercise or conversion | 4 | 4,876 | $918K |
| A | Grant or award | 2 | 2,117 | — |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 18 | 0 | 12 · $1.9M |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| REGN | Option / conversion M | August 10, 2026 | August 12, 2026 | 2d | 800 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| REGN | Sell S | August 10, 2026 | August 12, 2026 | 2d | 800 | $800 | $640K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Option / conversion M | August 10, 2026 | August 12, 2026 | 2d | 800 | $377 | $301K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Option / conversion M | February 19, 2026 | February 23, 2026 | 4d | 1,638 | — | — | 10b5-1 planderivative | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 4 | $790 | $3,160 | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 56 | $786 | $44K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 160 | $784 | $126K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 220 | $783 | $172K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 298 | $782 | $233K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 209 | $781 | $163K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 331 | $780 | $258K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 208 | $780 | $162K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 53 | $778 | $41K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 50 | $776 | $39K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Sell S | February 19, 2026 | February 23, 2026 | 4d | 49 | $775 | $38K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Option / conversion M | February 19, 2026 | February 23, 2026 | 4d | 1,638 | $377 | $617K | 10b5-1 plan | Form 4 ↗ | |
| REGN | Other A | January 2, 2026 | January 6, 2026 | 4d | 1,962 | — | — | derivative | Form 4 ↗ | |
| REGN | Other A | January 2, 2026 | January 6, 2026 | 4d | 155 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 12, 2026 | Form 4 | 0001681643-26-000006 | 3 | published | EDGAR ↗ |
| February 23, 2026 | Form 4 | 0001681643-26-000004 | 13 | published | EDGAR ↗ |
| January 6, 2026 | Form 4 | 0001681643-26-000002 | 2 | published | EDGAR ↗ |
Other insiders at REGENERON PHARMACEUTICALS, INC.
- RYAN ARTHUR F Director 50 rows
- MURPHY ANDREW J EVP Research 38 rows
- POON CHRISTINE A Director 28 rows
- Sanofi Insider 24 rows
- Pitofsky Jason SVP Controller 17 rows
- LAROSA JOSEPH J EVP General Counsel and Secret 9 rows
- Bassler Bonnie L Director 8 rows
- Guarini Kathryn Director 8 rows
- Fenimore Christopher R. EVP Finance CFO 6 rows
- McCourt Marion EVP Commercial 6 rows
Everyone on file, with contracts and lobbying under the company's name: REGENERON PHARMACEUTICALS, INC..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 3 | 18 | January 6, 2026 | August 12, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.